

# Michael J Carr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/590273/publications.pdf>

Version: 2024-02-01

21  
papers

177  
citations

1307594

7  
h-index

1199594

12  
g-index

21  
all docs

21  
docs citations

21  
times ranked

229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	1.5	40
2	Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. <i>Clinical Breast Cancer</i> , 2021, 21, e189-e193.	2.4	18
3	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 791-801.	1.5	18
4	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.5	14
5	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	1.8	11
6	Sentinel lymph node biopsy in melanoma: beyond histologic factors. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 29-38.	3.3	11
7	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. <i>World Journal of Surgery</i> , 2020, 44, 1283-1293.	1.6	8
8	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	1.5	8
9	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	1.5	8
10	Isolated limb infusion: Institutional protocol and implementation. <i>Journal of Surgical Oncology</i> , 2020, 122, 99-105.	1.7	7
11	Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. <i>Cancer Control</i> , 2020, 27, 107327482098301.	1.8	7
12	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	2.4	6
13	In-transit metastatic cutaneous melanoma: current management and future directions. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 201-211.	3.3	6
14	External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1637-1644.	1.5	5
15	Molecular Aspects of the Isolated Limb Infusion Procedure. <i>Biomedicines</i> , 2021, 9, 163.	3.2	3
16	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 19-29.	0.7	3
17	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. <i>Annals of Surgical Oncology</i> , 2021, 29, 804.	1.5	3
18	ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5119-5120.	1.5	1

#	ARTICLE	IF	CITATIONS
19	ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy. <i>Annals of Surgical Oncology</i> , 2021, 29, 802.	1.5	0
20	ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1647.	1.5	0
21	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	0